GlaxoSmithKline plc / Reliant Pharmaceuticals Inc.
2007 · Acquisition/Merger · $1.6B · Complete
Announcement Sentiment
88
Strongly positive
GlaxoSmithKline acquired Reliant Pharmaceuticals for $1.65B in cash, gaining Lovaza (omega-3-acid ethyl esters), a fast-growing prescription hypertriglyceridemia therapy that represented ~60% of Reliant's revenue. The deal added a US cardiovascular growth driver complementary to Coreg CR; generic entry from 2014 and FDA atrial-fibrillation warnings later eroded the franchise.